ABSTRACT
The experiment was designed to validate the effect of Artemisia annua and its novel commercial product (Navy Cox) on the control of necrotic enteritis (NE). A total of one hundred forty broiler chicks were randomly distributed into seven equal groups: G1, control negative; G2, infected with Eimeria (day 15) and C. perfringens (day 19); G3, treated with Navy Cox before challenge; G4, treated with Artemisia before challenge; G5, infected and then treated with Navy Cox; G6, infected and then treated with Artemisia; and G7, infected and treated with amoxicillin. Chicken response and immune organ indicants were recorded during the observation period (4 weeks). Whole blood and serum samples were collected for immunological evaluation, and tissue samples were collected for bacterial counts and estimation of mRNA expression of genes encoding apoptosis, tight junctions, and immunity. Chickens in the infected group revealed a significant decrease in RBCS, HB, PCV% total protein, Lysozyme, and nitric oxide activity in addition to leukocytosis, heterophilia, monocytosis, increase in cortisol, interleukins, and malondialdehyde. Treated groups displayed lower lesions, colony-forming units, and no mortality. Concurrently, a complete blood profile, antioxidants, and immune markers showed significant improvements. The mRNA expression levels of CASP, CLDN-1, OCLN, TJPI, MUC2, and cell-mediated immune response genes (p < 0.0001) were significantly alleviated in the treated groups compared with the challenged counterpart. This is the first-ever report on the efficacy valuation of Navy Cox compared to standard antibiotic treatment of clostridial NE. Navy Cox proved remarkable capability to minimize C. perfringens colonization in broiler intestines, modulation of mucus production, gut health integrity, immune organs, and immune response when used as a prophylactic agent in this form or naturally as Artemisia.
ABSTRACT
This experiment evaluated the impact of the dietary addition of 1,3-ß-glucans (GLU) on broiler chickens' growth, intestinal histology, blood biochemical parameters, and immunity. Two hundred three-day-old male broilers (Ross 308) (97.93 ± 0.19 g/chick) were randomly assigned into four treatments with five replicates, each containing ten birds, in a complete randomized design. The four treatments were formulated with 0, 50, 100, and 150 mg 1,3-ß-glucans kg−1 in broiler chicken diets. During the study, no significant impacts (p > 0.05) were observed in weight gain and feed conversion ratio (FCR) between treatment groups. Based on the results of total body weight gain and FCR, the optimal level of 1,3-ß-glucan is 120 mg Kg−1. The intestinal histomorphology was improved by GLU supplementation, as indicated by increased villi height and villi height to crypt depth ratio (p < 0.01). All levels of supplemental ß-1,3 glucan decreased the serum total cholesterol (TC), triglyceride levels, and low-density lipoprotein cholesterol (LDL-C) (p < 0.05). The serum levels of growth hormones (GH), triiodothyronine (T3), and thyroxine (T4) were increased in GLU-supplemented groups (p < 0.05). The serum immune indices (lysozyme activity, interleukin 10 (IL10), complement 3 (C3), and total protein levels) were increased in the GLU-supplemented groups (p < 0.05). Dietary GLU up-regulated the immunoexpression of CD3 (T-cell marker) and CD20 (B-cell marker) in the spleen of birds (p < 0.01). It can be concluded that 1,3-ß-glucan can be added to broiler chicken diets for improving the development and integrity of the intestine and enhancing the bird's immune status. The optimal level for 1,3-ß-glucan dietary supplementation was 120 mg Kg−1. Dietary 1,3-ß-glucan has a hypolipidemic effect and improves the hormonal profile of birds without affecting their growth rate.
